RxDoctor Payments Data

Anantha Krishna, MD

Cardiovascular Disease · Corbin, KYNPI 1740203447

Payments from drug & device makers

$1,874in general payments, 2019–2025

Across 110 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$355
  • AstraZeneca$343
  • Merck$291
  • Pfizer$234
  • Johnson & Johnson$153
  • Lexicon Pharmaceuticals, Inc.$121
  • plus $378 from 12 others

What the payments were for

  • Food & beverage$1,79496%
  • Education$804%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,874 in reported general payments places this provider in the 40th percentile of 258 cardiovascular disease providers in Kentucky.

See all cardiovascular disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$93,059
Medicare patients
807
Services billed
2,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban458$403,831
EntrestoSacubitril/Valsartan214$218,905
XareltoRivaroxaban103$108,600
FarxigaDapagliflozin Propanediol93$85,310
JardianceEmpagliflozin70$69,533
Flecainide Acetate222$9,027
Amiodarone Hcl119$8,551
Ranolazine ErRanolazine156$6,461
Metoprolol Succinate640$5,425
Dabigatran EtexilateDabigatran Etexilate Mesylate11$2,727
Diltiazem 24hr Er (Cd)Diltiazem Hcl109$2,387
Bumetanide154$1,856
Midodrine Hcl16$1,703
Atorvastatin Calcium205$1,657
Spironolactone289$1,570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$234$403,831458 claims
NovartisEntresto$355$218,905214 claims
Johnson & JohnsonXarelto$153$108,600103 claims
AstraZenecaFarxiga$343$85,31093 claims
Boehringer IngelheimJardiance$36$69,53370 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 258 cardiovascular disease providers in Kentucky.

Other cardiovascular disease in Corbin

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →